Subject(s)
Cardiology/standards , Electronic Health Records/standards , Forms and Records Control/standards , Heart Defects, Congenital , Pediatrics/standards , Consensus , Data Accuracy , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/physiopathology , Heart Defects, Congenital/therapy , Humans , Terminology as TopicABSTRACT
Myhre syndrome is a rare, distinctive syndrome due to specific gain-of-function mutations in SMAD4. The characteristic phenotype includes short stature, dysmorphic facial features, hearing loss, laryngotracheal anomalies, arthropathy, radiographic defects, intellectual disability, and a more recently appreciated spectrum of cardiovascular defects with a striking fibroproliferative response to surgical intervention. We report four newly described patients with typical features of Myhre syndrome who had (i) a mildly narrow descending aorta and restrictive cardiomyopathy; (ii) recurrent pericardial and pleural effusions; (iii) a large persistent ductus arteriosus with juxtaductal aortic coarctation; and (iv) restrictive pericardial disease requiring pericardiectomy. Additional information is provided about a fifth previously reported patient with fatal pericardial disease. A literature review of the cardiovascular features of Myhre syndrome was performed on 54 total patients, all with a SMAD4 mutation. Seventy percent had a cardiovascular abnormality including congenital heart defects (63%), pericardial disease (17%), restrictive cardiomyopathy (9%), and systemic hypertension (15%). Pericarditis and restrictive cardiomyopathy are associated with high mortality (three patients each among 10 deaths); one patient with restrictive cardiomyopathy also had epicarditis. Cardiomyopathy and pericardial abnormalities distinguish Myhre syndrome from other disorders caused by mutations in the TGF-ß signaling cascade (Marfan, Loeys-Dietz, or Shprintzen-Goldberg syndromes). We hypothesize that the expanded spectrum of cardiovascular abnormalities relates to the ability of the SMAD4 protein to integrate diverse signaling pathways, including canonical TGF-ß, BMP, and Activin signaling. The co-occurrence of congenital and acquired phenotypes demonstrates that the gene product of SMAD4 is required for both developmental and postnatal cardiovascular homeostasis. © 2016 Wiley Periodicals, Inc.
Subject(s)
Cardiovascular Abnormalities/diagnosis , Cardiovascular Abnormalities/genetics , Cryptorchidism/diagnosis , Cryptorchidism/genetics , Growth Disorders/diagnosis , Growth Disorders/genetics , Hand Deformities, Congenital/diagnosis , Hand Deformities, Congenital/genetics , Intellectual Disability/diagnosis , Intellectual Disability/genetics , Mutation , Phenotype , Smad4 Protein/genetics , Adolescent , Adult , Cardiovascular Abnormalities/therapy , Child , Cryptorchidism/therapy , Echocardiography , Exons , Facies , Female , Genetic Association Studies , Growth Disorders/therapy , Hand Deformities, Congenital/therapy , High-Throughput Nucleotide Sequencing , Humans , In Situ Hybridization, Fluorescence , Intellectual Disability/therapy , Magnetic Resonance Imaging , Male , Tomography, X-Ray Computed , Treatment Outcome , Ultrasonography , Young AdultSubject(s)
Cardiology/education , Fellowships and Scholarships/standards , Pediatrics/education , Adolescent , Child , Child, Preschool , Clinical Competence , Competency-Based Education/standards , Curriculum/standards , Dyslipidemias/diagnosis , Dyslipidemias/therapy , Educational Measurement , Goals , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/therapy , Heart Diseases/diagnosis , Heart Diseases/genetics , Heart Diseases/therapy , Humans , Infant , Infant, Newborn , TeachingSubject(s)
Advisory Committees , Cardiology/education , Internship and Residency/methods , Pediatrics/education , Societies, Medical , Advisory Committees/standards , Cardiology/standards , Clinical Competence/standards , Humans , Internship and Residency/standards , Pediatrics/standards , Societies, Medical/standardsSubject(s)
Cardiomyopathies/pathology , Cardiovascular Diseases/diagnostic imaging , Cardiovascular Diseases/diagnosis , Electrocardiography/methods , Adolescent , Adult , American Heart Association , Athletes , Cardiology/standards , Child , Cost-Benefit Analysis , Death, Sudden , Denmark , Electrodes , Female , Humans , Infant, Newborn , Israel , Italy , Male , Mass Screening/methods , Military Personnel , Predictive Value of Tests , Reproducibility of Results , Sensitivity and Specificity , Sudden Infant Death , Ultrasonography , United States , Young AdultABSTRACT
BACKGROUND: Changes in energy substrate metabolism are first responders to hemodynamic stress in the heart. We have previously shown that hexose-6-phosphate levels regulate mammalian target of rapamycin (mTOR) activation in response to insulin. We now tested the hypothesis that inotropic stimulation and increased afterload also regulate mTOR activation via glucose 6-phosphate (G6P) accumulation. METHODS AND RESULTS: We subjected the working rat heart ex vivo to a high workload in the presence of different energy-providing substrates including glucose, glucose analogues, and noncarbohydrate substrates. We observed an association between G6P accumulation, mTOR activation, endoplasmic reticulum (ER) stress, and impaired contractile function, all of which were prevented by pretreating animals with rapamycin (mTOR inhibition) or metformin (AMPK activation). The histone deacetylase inhibitor 4-phenylbutyrate, which relieves ER stress, also improved contractile function. In contrast, adding the glucose analogue 2-deoxy-d-glucose, which is phosphorylated but not further metabolized, to the perfusate resulted in mTOR activation and contractile dysfunction. Next we tested our hypothesis in vivo by transverse aortic constriction in mice. Using a micro-PET system, we observed enhanced glucose tracer analog uptake and contractile dysfunction preceding dilatation of the left ventricle. In contrast, in hearts overexpressing SERCA2a, ER stress was reduced and contractile function was preserved with hypertrophy. Finally, we examined failing human hearts and found that mechanical unloading decreased G6P levels and ER stress markers. CONCLUSIONS: We propose that glucose metabolic changes precede and regulate functional (and possibly also structural) remodeling of the heart. We implicate a critical role for G6P in load-induced mTOR activation and ER stress.
Subject(s)
Endoplasmic Reticulum Stress/physiology , Glucose/physiology , Heart/physiology , TOR Serine-Threonine Kinases/physiology , Animals , Humans , In Vitro Techniques , Male , Rats , Rats, Sprague-Dawley , Signal TransductionABSTRACT
We review our 16-year experience using the large, multi-institutional database of the University HealthSystem Consortium to study management and outcomes in congenital heart surgery for hypoplastic left heart syndrome, transposition of the great arteries, and neonatal coarctation. The advantages, limitations, and use of administrative databases by others to study congenital heart surgery are reviewed.
ABSTRACT
BACKGROUND: The purpose of this statement is to address the state of evidence on the routine use of pulse oximetry in newborns to detect critical congenital heart disease (CCHD). METHODS AND RESULTS: A writing group appointed by the American Heart Association and the American Academy of Pediatrics reviewed the available literature addressing current detection methods for CCHD, burden of missed and/or delayed diagnosis of CCHD, rationale of oximetry screening, and clinical studies of oximetry in otherwise asymptomatic newborns. MEDLINE database searches from 1966 to 2008 were done for English-language papers using the following search terms: congenital heart disease, pulse oximetry, physical examination, murmur, echocardiography, fetal echocardiography, and newborn screening. The reference lists of identified papers were also searched. Published abstracts from major pediatric scientific meetings in 2006 to 2008 were also reviewed. The American Heart Association classification of recommendations and levels of evidence for practice guidelines were used. In an analysis of pooled studies of oximetry assessment performed after 24 hours of life, the estimated sensitivity for detecting CCHD was 69.6%, and the positive predictive value was 47.0%; however, sensitivity varied dramatically among studies from 0% to 100%. False-positive screens that required further evaluation occurred in only 0.035% of infants screened after 24 hours. CONCLUSIONS: Currently, CCHD is not detected in some newborns until after their hospital discharge, which results in significant morbidity and occasional mortality. Furthermore, routine pulse oximetry performed on asymptomatic newborns after 24 hours of life, but before hospital discharge, may detect CCHD. Routine pulse oximetry performed after 24 hours in hospitals that have on-site pediatric cardiovascular services incurs very low cost and risk of harm. Future studies in larger populations and across a broad range of newborn delivery systems are needed to determine whether this practice should become standard of care in the routine assessment of the neonate.
Subject(s)
American Heart Association , Health Policy , Heart Defects, Congenital/diagnosis , Oximetry , Pediatrics , Societies, Medical , Cross-Sectional Studies , Evidence-Based Medicine , Heart Defects, Congenital/mortality , Humans , Infant, Newborn , Neonatal Screening , Sensitivity and Specificity , Survival Rate , Ultrasonography, Prenatal , United StatesABSTRACT
BACKGROUND: The purpose of this statement is to address the state of evidence on the routine use of pulse oximetry in newborns to detect critical congenital heart disease (CCHD). METHODS AND RESULTS: A writing group appointed by the American Heart Association and the American Academy of Pediatrics reviewed the available literature addressing current detection methods for CCHD, burden of missed and/or delayed diagnosis of CCHD, rationale of oximetry screening, and clinical studies of oximetry in otherwise asymptomatic newborns. MEDLINE database searches from 1966 to 2008 were done for English-language papers using the following search terms: congenital heart disease, pulse oximetry, physical examination, murmur, echocardiography, fetal echocardiography, and newborn screening. The reference lists of identified papers were also searched. Published abstracts from major pediatric scientific meetings in 2006 to 2008 were also reviewed. The American Heart Association classification of recommendations and levels of evidence for practice guidelines were used. In an analysis of pooled studies of oximetry assessment performed after 24 hours of life, the estimated sensitivity for detecting CCHD was 69.6%, and the positive predictive value was 47.0%; however, sensitivity varied dramatically among studies from 0% to 100%. False-positive screens that required further evaluation occurred in only 0.035% of infants screened after 24 hours. CONCLUSIONS: Currently, CCHD is not detected in some newborns until after their hospital discharge, which results in significant morbidity and occasional mortality. Furthermore, routine pulse oximetry performed on asymptomatic newborns after 24 hours of life, but before hospital discharge, may detect CCHD. Routine pulse oximetry performed after 24 hours in hospitals that have on-site pediatric cardiovascular services incurs very low cost and risk of harm. Future studies in larger populations and across a broad range of newborn delivery systems are needed to determine whether this practice should become standard of care in the routine assessment of the neonate.
Subject(s)
Evidence-Based Medicine , Heart Defects, Congenital/diagnosis , Heart Defects, Congenital/mortality , Neonatal Screening/standards , Oximetry/standards , Health Policy , Humans , Infant, Newborn , Neonatology , PrevalenceABSTRACT
For hypoplastic left heart syndrome (HLHS), there have been concerns regarding pulmonary artery growth and ventricular dysfunction after first stage surgery consisting of the Norwood procedure modified with a right ventricle-to-pulmonary artery conduit. We report our experience using cardiovascular magnetic resonance (CMR) to determine and follow pulmonary arterial growth and ventricular function in this cohort. Following first stage palliation, serial CMR was performed at 1 and 10 weeks post-operatively, followed by cardiac catheterization at 4-6 months. Thirty-four of 47 consecutive patients with HLHS (or its variations) underwent first stage palliation. Serial CMR was performed in 20 patients. Between studies, ejection fraction decreased (58 +/- 9% vs. 50 +/- 5%, p < 0.05). Pulmonary artery growth occurred on the left (6 +/- 1 mm vs. 4 +/- 1 mm at baseline, p < 0.05) but not significantly in the right. This trend continued to cardiac catheterization 4-6 months post surgery, with the left pulmonary artery of greater size than the right (8.8 +/- 2.2 mm vs. 6.7 +/- 1.9 mm, p < 0.05). By CMR, 5 had pulmonary artery stenoses initially, and at 2 months, 9 had stenoses. Three of the 9 underwent percutaneous intervention prior to the second stage procedure. In this cohort, reasonable growth of pulmonary arteries occurred following first stage palliation with this modification, although that growth was preferential to the left. Serial studies demonstrate worsening of ventricular function for the cohort. CMR was instrumental for detecting pulmonary artery stenosis and right ventricular dysfunction.
Subject(s)
Cardiovascular Surgical Procedures , Constriction, Pathologic/diagnosis , Hypoplastic Left Heart Syndrome/surgery , Magnetic Resonance Angiography/methods , Pulmonary Artery/growth & development , Ventricular Function , Cardiovascular Surgical Procedures/adverse effects , Cardiovascular Surgical Procedures/methods , Cohort Studies , Constriction, Pathologic/physiopathology , Contrast Media/administration & dosage , Follow-Up Studies , Humans , Hypoplastic Left Heart Syndrome/physiopathology , Image Enhancement/methods , Image Processing, Computer-Assisted , Infant , Infant, Newborn , Palliative Care/methods , Postoperative Complications/diagnosis , Postoperative Complications/physiopathology , Pulmonary Artery/pathology , Pulmonary Artery/physiopathology , Survival RateABSTRACT
A total of 14 patients with congenital heart disease underwent aortic valve repair, with transesophageal echocardiograms performed to determine severity, mechanism, and direction of aortic insufficiency (AI) jet to tailor the surgical approach. Patient age was 13 +/- 10 years, and accompanying diagnoses were: truncus arteriosus, subaortic stenosis, ventricular septal defect, and tetralogy of Fallot. Repeat transesophageal echocardiography was performed after each cardiopulmonary bypass run to determine residual AI and mechanism. Aortic valve leaflet number ranged from 2 to 4. AI was graded 2 to 4+, and postoperatively 0 to 2+. Primary mechanisms were: cusp prolapse (7), leaflet holes (4), restricted leaflet motion (2), and annular dilation (3). Patients required 1 to 3 cardiopulmonary bypass runs until primary AI mechanism was abolished. In all, 12 of 14 patients were free from death or repeated surgery at 2 years. Surgical repair of congenital AI may be aided by transesophageal echocardiographic guidance, with repeat short cardiopulmonary bypass as needed. Long-term studies are needed to determine durability of repair.
Subject(s)
Aortic Valve Insufficiency/diagnostic imaging , Aortic Valve Insufficiency/surgery , Echocardiography, Transesophageal , Heart Defects, Congenital/diagnostic imaging , Heart Defects, Congenital/surgery , Ultrasonography, Interventional , Adolescent , Adult , Child , Child, Preschool , Female , Humans , Infant , Male , Treatment OutcomeABSTRACT
Atrial septal defects are a common congenital heart defect and may complicate the course of a premature infant by imposing volume overload to the lungs. Surgical closure requires cardiopulmonary bypass and, frequently, a midline sternotomy. Recently, percutaneous transcatheter devices were approved for atrial septal defect closure but have been limited to use in larger children. Here we present the first known report of a transcatheter device closure of an atrial septal defect in a premature infant, which resulted in rapid improvement of the patient's respiratory status.
Subject(s)
Bronchopulmonary Dysplasia/complications , Cardiac Catheterization/instrumentation , Heart Septal Defects, Atrial/complications , Heart Septal Defects, Atrial/surgery , Infant, Premature, Diseases/surgery , Bronchopulmonary Dysplasia/therapy , Cardiac Surgical Procedures/instrumentation , Health Status , Humans , Infant , Infant, Newborn , Male , Time FactorsABSTRACT
The adenosine receptor system has been attributed with a broad range of both physiological and so-called 'retaliatory' functions in the heart and vessels. Despite many years of research, the precise roles of adenosine within the cardiovascular system continue to be debated, and new functions are continually emerging. Adenosine acts via 4 known G-protein-coupled receptor (GPCR) sub-types: A(1), A(2A), A(2B), and A(3) adenosine receptors (ARs). In addition to roles in cardiovascular control, these receptors may represent therapeutic targets, having been attributed with roles in modifying cell death and injury, inflammatory processes, and cardiac and vascular remodeling during/after ischemic or hypoxic insult. A number of models have been developed in which AR sub-types and adenosine handling enzymes have been genetically deleted or transgenically overexpressed in an attempt to more equivocally identify the regulatory functions of these proteins, to identify their potential value as therapeutic targets, and to uncover new regulatory functions of this receptor family. Findings generally support current dogma regarding cardioprotection via A(1) and A(3)ARs, and coronary vasoregulation via A(2)AR sub-types. However, some outcomes are both novel and controversial. This review outlines AR-modified murine models currently under study from the perspective of cardiovascular phenotype.
Subject(s)
Adenosine/metabolism , Cardiovascular Diseases/genetics , Heart/physiology , Receptors, Purinergic P1/genetics , Animals , Mice , PhenotypeABSTRACT
While inhibition of ischaemic contracture was one of the first documented cardioprotective actions of exogenously applied adenosine, it is not known whether this is a normal function of endogenous adenosine generated during ischaemic stress. Additionally, the relevance of delayed contracture to postischaemic outcome is unclear. We tested the ability of endogenous versus exogenous adenosine to modify contracture (and postischaemic outcomes) in C57/Bl6 mouse hearts. During ischaemia, untreated hearts developed peak contracture (PC) of 85 +/- 5 mmHg at 8.9 +/- 0.8 min, with time to reach 20 mmHg (time to onset of contracture; TOC) of 4.4 +/- 0.3 min. Adenosine (50 microm) delayed TOC to 6.7 +/- 0.6 min, as did pretreatment with 10 microm 2-chloroadenosine (7.2 +/- 0.5 min) or 50 nm of A(1) adenosine receptor (AR) agonist N(6)-cyclohexyladenosine (CHA) (6.7 +/- 0.3 min), but not A(2A)AR or A(3)AR agonists (20 nm 2-[4-(2-carboxyethyl) phenethylamino]-5' N-methylcarboxamidoadenosine (CGS21680) or 150 nm 2-chloro-N(6)-(3-iodobenzyl)-adenosine-5'-N-methyluronamide (Cl-IB-MECA), respectively). Adenosinergic contracture inhibition was eliminated by A(1)AR gene knockout (KO), mimicked by A(1)AR overexpression, and was associated with preservation of myocardial [ATP]. This adenosine-mediated inhibition of contracture was, however, only evident after prolonged (10 or 15 min) and not brief (3 min) pretreatment. Ischaemic contracture was also insensitive to endogenously generated adenosine, since A(1)AR KO, and non-selective and A(1)AR-selective antagonists (50 microm 8-sulphophenyltheophylline and 150 nm 8-cyclopentyl-1, 3-dipropylxanthine (DPCPX), respectively), all failed to alter intrinsic contracture development. Finally, delayed contracture with A(1)AR agonism/overexpression or ischaemic 2,3-butanedione monoxime (BDM; 5 microm to target Ca(2+) cross-bridge formation) was linked to enhanced postischaemic outcomes. In summary, adenosinergic inhibition of contracture is solely A(1)AR mediated; the response is 'supraphysiological', evident only with significant periods of pre-ischaemic AR agonism (or increased A(1)AR density); and ischaemic contracture appears insensitive to locally generated adenosine, potentially owing to the rapidity of contracture development versus the finite time necessary for expression of AR-mediated cardioprotection.
Subject(s)
Adenosine/metabolism , Myocardial Reperfusion Injury/physiopathology , Receptor, Adenosine A1/metabolism , Ventricular Function, Left , Ventricular Pressure , 2-Chloroadenosine/pharmacology , Adenine/analogs & derivatives , Adenine/pharmacology , Adenosine/pharmacology , Animals , In Vitro Techniques , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Myocardial Contraction , Myocardial Reperfusion Injury/metabolism , Receptor, Adenosine A1/drug effects , Receptor, Adenosine A1/genetics , Theophylline/analogs & derivatives , Theophylline/pharmacology , Time Factors , Ventricular Function, Left/drug effects , Ventricular Pressure/drug effects , Xanthines/pharmacologyABSTRACT
Activation of A(1) adenosine receptors (A(1)ARs) may be a crucial step in protection against myocardial ischemia-reperfusion (I/R) injury; however, the use of pharmacological A(1)AR antagonists to inhibit myocardial protection has yielded inconclusive results. In the current study, we have used mice with genetically modified A(1)AR expression to define the role of A(1)AR in intrinsic protection and ischemic preconditioning (IPC) against I/R injury. Normal wild-type (WT) mice, knockout mice with deleted (A(1)KO(-/-)) or single-copy (A(1)KO(+/-)) A(1)AR, and transgenic mice (A(1)TG) with increased cardiac A(1)AR expression underwent 45 min of left anterior descending coronary artery occlusion, followed by 60 min of reperfusion. Subsets of each group were preconditioned with short durations of ischemia (3 cycles of 5 min of occlusion and 5 min of reperfusion) before index ischemia. Infarct size (IF) in WT, A(1)KO(+/-), and A(1)KO(-/-) mice was (in % of risk region) 58 +/- 3, 60 +/- 4, and 61 +/- 2, respectively, and was less in A(1)TG mice (39 +/- 4, P < 0.05). A strong correlation was observed between A(1)AR expression level and response to IPC. IF was significantly reduced by IPC in WT mice (35 +/- 3, P < 0.05 vs. WT), A(1)KO(+/-) + IPC (48 +/- 4, P < 0.05 vs. A(1)KO(+/-)), and A(1)TG + IPC mice (24 +/- 2, P < 0.05 vs. A(1)TG). However, IPC did not decrease IF in A(1)KO(-/-) + IPC mice (63 +/- 2). In addition, A(1)KO(-/-) hearts subjected to global I/R injury demonstrated diminished recovery of developed pressure and diastolic function compared with WT controls. These findings demonstrate that A(1)ARs are critical for protection from myocardial I/R injury and that cardioprotection with IPC is relative to the level of A(1)AR gene expression.
Subject(s)
Ischemic Preconditioning, Myocardial/methods , Myocardial Ischemia/metabolism , Myocardial Ischemia/prevention & control , Myocardium/metabolism , Receptor, Adenosine A1/metabolism , Reperfusion Injury/metabolism , Reperfusion Injury/prevention & control , Animals , Disease Models, Animal , Mice , Mice, Inbred C57BL , Mice, Knockout , Receptor, Adenosine A1/deficiencyABSTRACT
This study evaluated the ability of A1 and A3 adenosine receptor (AR) agonism, and A1, A2A, A2B and A3AR antagonism (revealing "intrinsic" responses), to modify post-ischemic coronary dysfunction in mouse heart. Vascular function was assessed before and after 20 min global ischemia and 30-45 min reperfusion in Langendorff perfused C57/Bl6 mouse hearts. Ischemic insult impaired coronary sensitivity to the endothelial-dependent dilators ADP (pEC50=6.8+/-0.1 vs. 7.6+/-0.1, non-ischemic) and acetylcholine (pEC50=6.1+/-0.1 vs. 7.3+/-0.1 in non-ischemic), and for the mixed endothelial-dependent/independent dilator 2-chloroadenosine (pEC50=7.5+/-0.1 vs. 8.4+/-0.1, non-ischemic). Endothelium-independent dilation in response to nitroprusside was unaltered (pEC50=7.0+/-0.1 vs. 7.1+/-0.1 in non-ischemic). Pre-treatment with a selective A1AR agonist (50 nM CHA) failed to modify coronary dysfunction, whereas A1AR antagonism (200 nM DPCPX) worsened the effects of I/R (2-chloroadenosine pEC50=6.9+/-0.1). Conversely, A3AR agonism (100 nM Cl-IB-MECA) did reduce effects of I/R (pEC50s=8.0+/-0.1 and 7.3+/-0.1 for 2-chloroadenosine and ADP, respectively), whereas antagonism (100 nM MRS1220) was without effect. While A2AAR agonism could not be assessed (due to pronounced vasodilatation), A2AAR antagonism (100 nM SCH58261) was found to exert no effect, and antagonism of A2BARs (50 nM MRS1754) was also ineffective. The protective actions of A3AR agonism were also manifest as improved reactive hyperemic responses. Interestingly, post-ischemic coronary dysfunction was also limited by: Na+-H+ exchange (NHE) inhibition with 10 or 50 microM BIIB-513 (2-chloroadenosine pEC50s=7.8+/-0.1, either dose), an effect not additive with A3AR agonism; Ca2+ antagonism with 0.3 microM verapamil (2-chloroadenosine pEC50=7.9+/-0.1); and Ca2+ desensitization with 5 mM BDM (2-chloroadenosine pEC50=7.8+/-0.1). In contrast, endothelin antagonism (200 nM PD142893) and anti-oxidant therapy (300 microM MPG+150 U/ml SOD+600 U/ml catalase) were ineffective. Our data collectively confirm that ischemia selectively impairs endothelial function and reactive hyperemia independently of blood cells. Vascular injury is intrinsically limited by endogenous (but not exogenous) activation of A1ARs, whereas exogenous A3AR activation further limits dysfunction (improving post-ischemic vasoregulation). Finally, findings suggest this form of post-ischemic coronary injury is unrelated to endothelin or oxidant stress, but may involve modulation of Ca2+ overload and/or related ionic perturbations.